ReviewBlood cancer journal2018
Waldenström macroglobulinemia treatment algorithm 2018.
Review in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.Blood cancer journal · 2023Pooled it
- Knowledge, Attitudes, and Practices Towards Waldenström's Macroglobulinemia Among Patients and Their Family Members.International journal of general medicine · 2025Article
- Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline.HemaSphere · 2022Article
- Conditional relative survival in Waldenström's macroglobulinaemia: a population-based study in The Netherlands.British journal of haematology · 2022Article
- Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.British journal of haematology · 2022Article
- Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.Frontiers in oncology · 2022Review
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia.Oncotarget · 2019Article
- Peripheral Nervous System Involvement in Lymphoproliferative Disorders.Mediterranean journal of hematology and infectious diseases · 2018Review
- Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management.Journal of the advanced practitioner in oncologyArticle
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Recent introduction of MYD88 mutational analysis has been very useful for diagnostic purposes but is unclear what effect it might have on the prognosis or response rate to therapy. An algorithm is provided on the management of asymptomatic individuals and the sequence used for chemotherapeutic intervention of symptomatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.